Annual report pursuant to Section 13 and 15(d)

SEGMENT REPORTING - Net Sales and Segment Profit (Details)

v3.22.1
SEGMENT REPORTING - Net Sales and Segment Profit (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2021
Mar. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Segment Reporting Information [Line Items]        
Net Sales     $ 15,374 $ 12,117
Gross profit     6,809 7,413
Non-cash share based compensation     (11,451) (1,652)
Depreciation and amortization     (1,768) (1,854)
Goodwill impairment     (18,508) (1,682)
Loss from operations     (57,207) (28,528)
(Gain) loss on debt extinguishment, net     (3,262) 2,360
Gain on remeasurement of warrant liability     (16,856) (10,780)
Loss on fair value of derivative instrument     0 657
Loss on investments     0 464
Foreign exchange loss     1,276 491
Interest expense     6,818 4,455
Other income, net     (502) (284)
Loss from operations before income taxes and equity investment loss     (44,681) (25,891)
Cannabinoid        
Segment Reporting Information [Line Items]        
Goodwill impairment $ (18,508)   (18,508) 0
Non-Cannabinoid        
Segment Reporting Information [Line Items]        
Goodwill impairment   $ (1,682) 0 (1,682)
Operating Segments        
Segment Reporting Information [Line Items]        
Net Sales     15,374 12,117
Gross profit     (14,284) (16,935)
Operating Segments | Cannabinoid        
Segment Reporting Information [Line Items]        
Net Sales     3,242 2,511
Gross profit     (16,915) (18,798)
Operating Segments | Non-Cannabinoid        
Segment Reporting Information [Line Items]        
Net Sales     12,132 9,606
Gross profit     2,631 1,863
Other        
Segment Reporting Information [Line Items]        
Unallocated corporate expenses     (11,196) (6,405)
Non-cash share based compensation     (11,451) (1,652)
Depreciation and amortization     (1,768) (1,854)
Goodwill impairment     (18,508) (1,682)
Loss from operations     $ (57,207) $ (28,528)